gliclazide has been researched along with Disease Models, Animal in 21 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combined treatment of deprenyl and gliclazide may contribute to the control of the physiopathological mechanisms underlying both the process of aging and type 2 diabetes by reducing oxidant stress and DNA damage, improving antioxidant status, and increasing survival, and may have implications for further clinical studies." | 3.73 | Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model. ( Alper, G; Caglayan, O; Duman, E; Irer, S; Yilmaz, C, 2005) |
| "Treatment with empagliflozin showed a significant amelioration of behavioral/neurological functions and histopathological changes observed in brain tissues of hyperglycemic rats subjected to cerebral I/R injury." | 1.56 | Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. ( Abdel-Latif, RG; Amin, EF; Rifaai, RA, 2020) |
| " The solubility, dissolution rate and bioavailability of gliclazide SGNCs were significantly improved compared to pure gliclazide." | 1.51 | Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ( Bhattamisra, SK; Krishnamoorthy, R; Panda, BP; Patnaik, S; Seng, LB; Shivashekaregowda, NKH, 2019) |
| "Gliclazide-treated had similar kidney index, but lower glucose levels, sCr, BUN, and MAU, compared with both saline and 4-PBA-treated diabetic rats or saline-treated TM rats." | 1.48 | Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy. ( Ren, X; Wang, X; Zhang, M; Zhang, YW, 2018) |
| "Gliclazide (G) is a commonly prescribed drug for Type 2 diabetes (T2D)." | 1.43 | A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. ( Al-Salami, H; Arfuso, F; Chen-Tan, N; Mathavan, S, 2016) |
| "Gliclazide was administered intravenously into the right jugular vein for 12h simultaneously with the reperfusion." | 1.40 | Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats. ( Li, H; Ma, M; Tan, F; Yu, Y, 2014) |
| "The rats with diabetic gastroparesis induced by injecting alloxan and giving 200% Radix Rehmanniae preparata were divided into four groups randomly: Tangweian high dosage group, Tangweian low dosage group, motilium control group and the model control group, 10 rats each group." | 1.35 | [Effects of Tangweian granule on 5-HT(2A)R in rat model with diabetic gastroparesis]. ( Liu, DW; Qian, QH; Qian, WB; Wang, ZC; Zhao, Y, 2008) |
| "Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring." | 1.35 | Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. ( Louro, T; Matafome, P; Monteiro, P; Nunes, E; Seiça, R; Sena, CM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Rathish, IG | 1 |
| Javed, K | 1 |
| Bano, S | 1 |
| Ahmad, S | 1 |
| Alam, MS | 1 |
| Pillai, KK | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| García-García, A | 1 |
| Rojas, S | 1 |
| Rivas-García, L | 1 |
| Navarro-Hortal, MD | 1 |
| Romero-Márquez, JM | 1 |
| Fernández-Bolaños, JG | 1 |
| Choquesillo-Lazarte, D | 1 |
| Salinas-Castillo, A | 1 |
| López, Ó | 1 |
| Quiles, JL | 1 |
| Rodríguez-Diéguez, A | 1 |
| Panda, BP | 1 |
| Krishnamoorthy, R | 1 |
| Bhattamisra, SK | 1 |
| Shivashekaregowda, NKH | 1 |
| Seng, LB | 1 |
| Patnaik, S | 1 |
| Amin, EF | 1 |
| Rifaai, RA | 1 |
| Abdel-Latif, RG | 1 |
| Zhang, YW | 1 |
| Wang, X | 1 |
| Ren, X | 1 |
| Zhang, M | 1 |
| Tan, F | 1 |
| Li, H | 1 |
| Ma, M | 1 |
| Yu, Y | 1 |
| Mathavan, S | 1 |
| Chen-Tan, N | 1 |
| Arfuso, F | 1 |
| Al-Salami, H | 1 |
| Qian, QH | 1 |
| Wang, ZC | 1 |
| Zhao, Y | 1 |
| Liu, DW | 1 |
| Qian, WB | 1 |
| Palsamy, P | 1 |
| Subramanian, S | 1 |
| el-Batran, SA | 1 |
| el-Shenawy, SM | 1 |
| Nofal, SM | 1 |
| Abdel-Salam, OM | 1 |
| Arbid, MS | 1 |
| Alper, G | 1 |
| Irer, S | 1 |
| Duman, E | 1 |
| Caglayan, O | 1 |
| Yilmaz, C | 1 |
| Chen, J | 1 |
| Li, WL | 1 |
| Wu, JL | 1 |
| Ren, BR | 1 |
| Zhang, HQ | 1 |
| Al-Kassas, RS | 1 |
| Al-Gohary, OM | 1 |
| Al-Faadhel, MM | 1 |
| Sena, CM | 1 |
| Louro, T | 1 |
| Matafome, P | 1 |
| Nunes, E | 1 |
| Monteiro, P | 1 |
| Seiça, R | 1 |
| Bouskela, E | 1 |
| Cyrino, FZ | 1 |
| Conde, CM | 1 |
| Garcia, AA | 1 |
| Misawa, K | 1 |
| Ichikawa, K | 1 |
| Ojima, K | 1 |
| Hamano, S | 1 |
| Kitamura, T | 1 |
| Komatsu, H | 1 |
| Marquié, G | 2 |
| Brindley, DN | 1 |
| Hadjiisky, P | 1 |
| Arnaud, O | 1 |
| Duhault, J | 1 |
| Masaki, Y | 1 |
| Tanigawa, K | 1 |
| Ohguni, S | 1 |
| Note, S | 1 |
1 review available for gliclazide and Disease Models, Animal
| Article | Year |
|---|---|
Metabolic approach to atherosclerosis: effect of gliclazide.
Topics: Animals; Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Disease Models, Animal; Glicla | 1992 |
20 other studies available for gliclazide and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relat | 2009 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
A gliclazide complex based on palladium towards Alzheimer's disease: promising protective activity against Aβ-induced toxicity in
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Caenorhabditis elegans; Co | 2022 |
Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model.
Topics: Animals; Biological Availability; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diab | 2019 |
Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Disease Models, Animal; Gliclazide; Glucosides; Hyperglyce | 2020 |
Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Gliclazide | 2018 |
Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats.
Topics: Animals; Apoptosis; Blood Glucose; Brain; Brain Ischemia; Disease Models, Animal; Gene Expression; G | 2014 |
A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes.
Topics: Alginates; Animals; Bile Acids and Salts; Blood Glucose; Capsules; Cell Survival; Diabetes Mellitus, | 2016 |
[Effects of Tangweian granule on 5-HT(2A)R in rat model with diabetic gastroparesis].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Drugs, Chinese Herb | 2008 |
Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats.
Topics: Administration, Oral; Animals; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Disease Mod | 2009 |
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Blood Proteins; Carbamates; Cholesterol, LDL; Diabetes Mellitus, Ex | 2004 |
Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aging; Animals; Antioxidants; Blood Glucose; Body Weight; Deoxyguanosin | 2005 |
Hypoglycemic effects of a sesquiterpene glycoside isolated from leaves of loquat (Eriobotrya japonica (Thunb.) Lindl.).
Topics: Administration, Oral; Alloxan; Animals; Blood Glucose; Carbohydrate Sequence; Diabetes Mellitus, Exp | 2008 |
Controlling of systemic absorption of gliclazide through incorporation into alginate beads.
Topics: Administration, Oral; Alginates; Animals; Blood Glucose; Chemistry, Pharmaceutical; Delayed-Action P | 2007 |
Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcholine; Animals; Antioxidants; Body Weight; Deoxyguanosine; Diab | 2009 |
Microvascular permeability with sulfonylureas in normal and diabetic hamsters.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Capillary Permeability; Cricetinae; Dextrans; D | 1997 |
Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs.
Topics: Animals; Anti-Bacterial Agents; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Anim | 2001 |
Preventive effect of gliclazide on experimental atherosclerosis in rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol, Dietary; Diet, Atherogenic; Disease Models, Animal; F | 1978 |
Development of macroangiopathy in sand rats (Psammomys obesus), an animal model of non-insulin-dependent diabetes mellitus: effect of gliclazide.
Topics: Animals; Cholesterol, Dietary; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Ani | 1991 |
Rat fetal islets as a useful model for the study of insulin release failure.
Topics: Animals; Colforsin; Culture Techniques; Disease Models, Animal; Female; Fetus; Gliclazide; Insulin; | 1987 |